Hopp Katharina, Cogal Andrea G, Bergstralh Eric J, Seide Barbara M, Olson Julie B, Meek Alicia M, Lieske John C, Milliner Dawn S, Harris Peter C
Division of Nephrology and Hypertension.
Division of Biomedical Statistics and Informatics.
J Am Soc Nephrol. 2015 Oct;26(10):2559-70. doi: 10.1681/ASN.2014070698. Epub 2015 Feb 2.
Primary hyperoxaluria (PH) is a rare autosomal recessive disease characterized by oxalate accumulation in the kidneys and other organs. Three loci have been identified: AGXT (PH1), GRHPR (PH2), and HOGA1 (PH3). Here, we compared genotype to phenotype in 355 patients in the Rare Kidney Stone Consortium PH registry and calculated prevalence using publicly available whole-exome data. PH1 (68.4% of families) was the most severe PH type, whereas PH3 (11.0% of families) showed the slowest decline in renal function but the earliest symptoms. A group of patients with disease progression similar to that of PH3, but for whom no mutation was detected (11.3% of families), suggested further genetic heterogeneity. We confirmed that the AGXT p.G170R mistargeting allele resulted in a milder PH1 phenotype; however, other potential AGXT mistargeting alleles caused more severe (fully penetrant) disease. We identified the first PH3 patient with ESRD; a homozygote for two linked, novel missense mutations. Population analysis suggested that PH is an order of magnitude more common than determined from clinical cohorts (prevalence, approximately 1:58,000; carrier frequency, approximately 1:70). We estimated PH to be approximately three times less prevalent among African Americans than among European Americans because of a limited number of common European origin alleles. PH3 was predicted to be as prevalent as PH1 and twice as common as PH2, indicating that PH3 (and PH2) cases are underdiagnosed and/or incompletely penetrant. These results highlight a role for molecular analyses in PH diagnostics and prognostics and suggest that wider analysis of the idiopathic stone-forming population may be beneficial.
原发性高草酸尿症(PH)是一种罕见的常染色体隐性疾病,其特征是草酸盐在肾脏和其他器官中蓄积。已确定了三个基因座:AGXT(PH1)、GRHPR(PH2)和HOGA1(PH3)。在此,我们比较了罕见肾结石联盟PH登记处355例患者的基因型与表型,并使用公开的全外显子数据计算患病率。PH1(占家族的68.4%)是最严重的PH类型,而PH3(占家族的11.0%)肾功能下降最慢,但症状出现最早。一组疾病进展与PH3相似但未检测到突变的患者(占家族的11.3%)提示存在进一步的遗传异质性。我们证实AGXT p.G170R错靶等位基因导致较轻的PH1表型;然而,其他潜在的AGXT错靶等位基因导致更严重(完全显性)的疾病。我们鉴定出首例终末期肾病的PH3患者;该患者为两个连锁的新型错义突变的纯合子。群体分析表明,PH的实际患病率比临床队列研究确定的患病率高一个数量级(患病率约为1:58,000;携带频率约为1:70)。由于常见的欧洲起源等位基因数量有限,我们估计非裔美国人中PH的患病率比欧洲裔美国人低约三倍。预计PH3的患病率与PH1相同,是PH2的两倍,这表明PH3(和PH2)病例未得到充分诊断和/或存在不完全显性。这些结果突出了分子分析在PH诊断和预后中的作用,并表明对特发性结石形成人群进行更广泛的分析可能有益。